Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 31;19(1):37.
doi: 10.1186/s13019-024-02511-6.

Thymoma negatively affects the neurological outcome of myasthenia gravis after thymectomy: a propensity score matching study

Affiliations

Thymoma negatively affects the neurological outcome of myasthenia gravis after thymectomy: a propensity score matching study

Wenxin Tian et al. J Cardiothorac Surg. .

Abstract

Background: Thymoma and myasthenia gravis (MG) interact with each other. This study aimed to evaluate the effects of thymoma on neurological outcome of MG patients after thymectomy using the propensity score matching (PSM) method.

Methods: Consecutive patients with MG who underwent thymectomy at Beijing Hospital between January 2012 and August 2021 were retrospectively enrolled. Clinical and follow-up data were collected. Statistical analysis was performed using SPSS 23.0 software. PSM was performed to eliminate selection bias.

Results: A total of 456 patients were included in this study. Thymoma was present in 138 (30.3%) patients. The median follow-up time was 72 (range, 12-135) months. At the last follow-up, a lower proportion of thymomatous MG patients achieved complete stable remission (CSR) compared with non-thymomatous MG patients (P = 0.011), and the effective rate [CSR + pharmatologic remission (PR) + minimal manifestations (MM)] of thymomatous MG patients was also lower (P = 0.037). Considering time to CSR, Kaplan-Meier analysis showed thymomatous MG patients had lower cumulative CSR rate than non-thymomatous MG patients (log-rank, P = 0.019). After PSM, 105 pairs of patients were matched successfully. For the matched patients, thymomatous MG patients had a lower CSR rate and a lower effective rate (P = 0.002, 0.039, respectively), and K-M analysis still showed thymomatous MG patients had lower cumulative CSR rate (log-rank, P = 0.048). Multivariate Cox analysis demonstrated that thymoma (HR: 0.592, 95% CI 0.389-0.900, P = 0.014), older age at the time of surgery (HR: 0.971, 95% CI 0.953-0.990, P = 0.003), and preoperative course of MG > 12 months (HR: 0.474, 95% CI 0.317-0.708, P = 0.000) were negative predictive factors for CSR.

Conclusions: Thymoma had a negative effect on the neurological outcome of MG after thymectomy. MG patients with old age and a preoperative course of longer than one year had a lower probability of achieving CSR.

Keywords: Myasthenia gravis; Neurological outcome; Propensity score matching; Thymectomy; Thymoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A Cumulative CSR rates of thymomatous MG patients and non-thymomatous MG patients before PSM. Thymomatous MG patients had a lower CSR rate compared with non-thymomatous MG patients (log-rank, P = 0.019). B Cumulative CSR rates of thymomatous MG patients and non-thymomatous MG patients after PSM. Thymomatous MG patients still had a lower CSR rate compared with non-thymomatous MG patients (log-rank, P = 0.031)

References

    1. Meisel A, Baggi F, Behin A, Evoli A, Kostera-Pruszczyk A, Mantegazza R, et al. Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal. Eur J Neurol. 2023;30:266–282. doi: 10.1111/ene.15565. - DOI - PubMed
    1. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18:259–268. doi: 10.1016/S1474-4422(18)30392-2. - DOI - PMC - PubMed
    1. Yang J, Liu C, Li T, Li C. Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia. Int J Neurosci. 2017;127:785–789. doi: 10.1080/00207454.2016.1257993. - DOI - PubMed
    1. Barnett C, Katzberg HD, Keshavjee S, Bril V. Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. Orphanet J Rare Dis. 2014;9:214. doi: 10.1186/s13023-014-0214-5. - DOI - PMC - PubMed
    1. Cataneo AJM, Felisberto G, Jr, Cataneo DC. Thymectomy in nonthymomatous myasthenia gravis-systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13:99. doi: 10.1186/s13023-018-0837-z. - DOI - PMC - PubMed